Crossmark

Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

Published Online: 2019-08-22

Published Print: 2019-12

Authors

Li, Fengzhi http://orcid.org/0000-0002-2299-7951
Aljahdali, Ieman

Ling, Xiang
Funding

Funding for this research was provided by:

NIH/NCI (R44CA176937, R43CA221389)
License Information

Text and Data Mining valid from 2019-08-22

Version of Record valid from 2019-08-22
More Information

Article History

Received: 18 July 2019

Accepted: 6 August 2019

First Online: 22 August 2019

Ethics approval and consent to participate

: This review article contains both animal model data and human clinical data. However, these data were performed in published papers with appropriate ethics approval. For the ethics approval is not applicable.

: The unpublished observations or data mentioned in this review article are from the Authors’ research team. Consent form is available upon request.

: FL118 and FL118 core structure-based analogs will be further developed in Canget BioTekpharma LLC (ExternalRef removed), a Roswell Park Comprehensive Cancer Center-spinoff company. FL and XL are two of the eighteen initial investors of Canget for development of FL118 and FL118 core structure-relevant anticancer agents.

Document is current